Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Engineering HSV-1 Vectors for Gene Therapy.

Goins WF, Huang S, Hall B, Marzulli M, Cohen JB, Glorioso JC.

Methods Mol Biol. 2020;2060:73-90. doi: 10.1007/978-1-4939-9814-2_4.

PMID:
31617173
2.

Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9.

Wirsching HG, Arora S, Zhang H, Szulzewsky F, Cimino PJ, Quéva C, Houghton AM, Glorioso JC, Weller M, Holland EC.

Neuro Oncol. 2019 Aug 15. pii: noz145. doi: 10.1093/neuonc/noz145. [Epub ahead of print] No abstract available.

PMID:
31412117
3.

Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, Weller M, Finer M, Quéva C, Glorioso JC, Houghton AM, Holland EC.

JCI Insight. 2019 Jul 11;4(13). pii: 128217. doi: 10.1172/jci.insight.128217. eCollection 2019 Jul 11.

4.

The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1α on bladder overactivity and nociception.

Majima T, Mori K, Kadekawa K, Takai S, Funahashi Y, Reinhart B, Goins WF, Gotoh M, Glorioso JC, Yoshimura N.

Neurourol Urodyn. 2019 Feb;38(2):582-590. doi: 10.1002/nau.23882. Epub 2018 Nov 29.

PMID:
30499116
5.

A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors.

Marzulli M, Mazzacurati L, Zhang M, Goins WF, Hatley ME, Glorioso JC, Cohen JB.

J Gene Ther. 2018 Oct;3(1). doi: 10.13188/2381-3326.1000007. Epub 2018 Oct 18.

6.

Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System.

Artusi S, Miyagawa Y, Goins WF, Cohen JB, Glorioso JC.

Diseases. 2018 Aug 14;6(3). pii: E74. doi: 10.3390/diseases6030074. Review.

7.

Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression.

Han F, Miyagawa Y, Verlengia G, Ingusci S, Soukupova M, Simonato M, Glorioso JC, Cohen JB.

J Virol. 2018 Aug 16;92(17). pii: e00536-18. doi: 10.1128/JVI.00536-18. Print 2018 Sep 1.

8.

Corrigendum to 'Morphological Changes in Different Populations of Bladder Afferent Neurons Detected by Herpes Simplex Virus (HSV) Vectors with Cell-type-specific Promoters in Mice with Spinal Cord Injury' [Neuroscience 364 (2017) 190-201].

Shimizu N, Doyal MF, Goins WF, Kadekawa K, Wada N, Kanai AJ, de Groat WC, Hirayama A, Uemura H, Glorioso JC, Yoshimura N.

Neuroscience. 2018 Jun 15;381:161. doi: 10.1016/j.neuroscience.2018.04.021. Epub 2018 Apr 26. No abstract available.

9.

Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1α in a rat cystitis model induced by hydrogen peroxide.

Takai S, Majima T, Reinhart B, Goins WF, Funahashi Y, Gotoh M, Tyagi P, Glorioso JC, Yoshimura N.

Gene Ther. 2018 Jan;25(1):20-26. doi: 10.1038/gt.2017.94. Epub 2017 Oct 20.

10.

Gene therapy-from small beginnings to where we are now.

Glorioso JC, Lemoine N.

Gene Ther. 2017 Sep;24(9):495-496. doi: 10.1038/gt.2017.23. No abstract available.

PMID:
28963564
11.

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury.

Shimizu N, Doyal MF, Goins WF, Kadekawa K, Wada N, Kanai AJ, de Groat WC, Hirayama A, Uemura H, Glorioso JC, Yoshimura N.

Neuroscience. 2017 Nov 19;364:190-201. doi: 10.1016/j.neuroscience.2017.09.024. Epub 2017 Sep 20. Erratum in: Neuroscience. 2018 Apr 25;:.

12.

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.

Miyagawa Y, Verlengia G, Reinhart B, Han F, Uchida H, Zucchini S, Goins WF, Simonato M, Cohen JB, Glorioso JC.

Mol Ther Methods Clin Dev. 2017 Jun 16;6:79-90. doi: 10.1016/j.omtm.2017.06.001. eCollection 2017 Sep 15.

13.

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system.

Verlengia G, Miyagawa Y, Ingusci S, Cohen JB, Simonato M, Glorioso JC.

Sci Rep. 2017 May 4;7(1):1507. doi: 10.1038/s41598-017-01635-1.

14.

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats.

Iida T, Yi H, Liu S, Ikegami D, Zheng W, Liu Q, Takahashi K, Kashiwagi Y, Goins WF, Glorioso JC, Hao S.

Gene Ther. 2017 May;24(5):314-324. doi: 10.1038/gt.2017.22. Epub 2017 Apr 3.

PMID:
28368370
15.

Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.

Uchida H, Hamada H, Nakano K, Kwon H, Tahara H, Cohen JB, Glorioso JC.

Curr Cancer Drug Targets. 2018;18(2):162-170. doi: 10.2174/1568009617666170206105855. Review.

PMID:
28176649
16.

Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.

Okubo Y, Uchida H, Wakata A, Suzuki T, Shibata T, Ikeda H, Yamaguchi M, Cohen JB, Glorioso JC, Tagaya M, Hamada H, Tahara H.

J Virol. 2016 Nov 28;90(24):11096-11105. Print 2016 Dec 15.

17.

Retargeting of herpes simplex virus (HSV) vectors.

Goins WF, Hall B, Cohen JB, Glorioso JC.

Curr Opin Virol. 2016 Dec;21:93-101. doi: 10.1016/j.coviro.2016.08.007. Epub 2016 Sep 8. Review.

18.

Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells.

Laemmle LL, Cohen JB, Glorioso JC.

Open Biotechnol J. 2016;10:248-257. Epub 2016 Jun 30.

19.

An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain.

Reinhart B, Goins WF, Harel A, Chaudhry S, Goss JR, Yoshimura N, de Groat WC, Cohen JB, Glorioso JC.

Mol Ther Methods Clin Dev. 2016 Jun 22;3:16040. doi: 10.1038/mtm.2016.40. eCollection 2016.

20.

Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.

Shibata T, Uchida H, Shiroyama T, Okubo Y, Suzuki T, Ikeda H, Yamaguchi M, Miyagawa Y, Fukuhara T, Cohen JB, Glorioso JC, Watabe T, Hamada H, Tahara H.

Gene Ther. 2016 Jun;23(6):479-88. doi: 10.1038/gt.2016.17. Epub 2016 Feb 23.

PMID:
26905369
21.

Moving toward a gene therapy for Huntington's disease.

Glorioso JC, Cohen JB, Carlisle DL, Munoz-Sanjuan I, Friedlander RM.

Gene Ther. 2015 Dec;22(12):931-3. doi: 10.1038/gt.2015.102. No abstract available.

PMID:
26633828
22.

Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility.

Wang PY, Swain HM, Kunkler AL, Chen CY, Hutzen BJ, Arnold MA, Streby KA, Collins MH, Dipasquale B, Stanek JR, Conner J, van Kuppevelt TH, Glorioso JC, Grandi P, Cripe TP.

Gene Ther. 2016 Feb;23(2):135-43. doi: 10.1038/gt.2015.105. Epub 2015 Nov 19.

23.

Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.

Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, Chiocca EA.

J Clin Invest. 2015 Nov 2;125(11):4269-80. doi: 10.1172/JCI80713. Epub 2015 Oct 20.

24.

Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats.

Majima T, Funahashi Y, Takai S, Goins WF, Gotoh M, Tyagi P, Glorioso JC, Yoshimura N.

Hum Gene Ther. 2015 Nov;26(11):734-42. doi: 10.1089/hum.2015.026. Epub 2015 Aug 31.

25.

Current gene therapy using viral vectors for chronic pain.

Guedon JM, Wu S, Zheng X, Churchill CC, Glorioso JC, Liu CH, Liu S, Vulchanova L, Bekker A, Tao YX, Kinchington PR, Goins WF, Fairbanks CA, Hao S.

Mol Pain. 2015 May 13;11:27. doi: 10.1186/s12990-015-0018-1. Review.

26.

Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.

Miyagawa Y, Marino P, Verlengia G, Uchida H, Goins WF, Yokota S, Geller DA, Yoshida O, Mester J, Cohen JB, Glorioso JC.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1632-41. doi: 10.1073/pnas.1423556112. Epub 2015 Mar 16.

27.

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, Hildeman DA, Cripe TP.

Mol Ther Oncolytics. 2015 Jan 21;1:14010. doi: 10.1038/mto.2014.10. eCollection 2015.

28.

Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.

Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Amankulor N, Cohen JB, Glorioso JC, Grandi P.

Mol Ther. 2015 Jan;23(1):99-107. doi: 10.1038/mt.2014.177. Epub 2014 Sep 9. Erratum in: Mol Ther. 2015 Jan;23(1):215. Chiocca, Nino [corrected to Chiocca, Ennio A].

29.

Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin.

Guedon JM, Zhang M, Glorioso JC, Goins WF, Kinchington PR.

Gene Ther. 2014 Jul;21(7):694-702. doi: 10.1038/gt.2014.43. Epub 2014 May 15.

30.

Engineering HSV-1 vectors for gene therapy.

Goins WF, Huang S, Cohen JB, Glorioso JC.

Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.

PMID:
24671677
31.

Herpes simplex viral vectors: late bloomers with big potential.

Glorioso JC.

Hum Gene Ther. 2014 Feb;25(2):83-91. doi: 10.1089/hum.2014.2501. Review. No abstract available.

32.

Progress in gene therapy for neurological disorders.

Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC.

Nat Rev Neurol. 2013 May;9(5):277-91. doi: 10.1038/nrneurol.2013.56. Epub 2013 Apr 23. Review. Erratum in: Nat Rev Neurol. 2013 Jun;9(6):298.

33.

Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Yokoyama H, Oguchi T, Goins WF, Goss JR, Nishizawa O, de Groat WC, Wolfe D, Krisky DM, Glorioso JC, Yoshimura N.

Hum Gene Ther. 2013 Feb;24(2):170-80. doi: 10.1089/hum.2011.180. Epub 2013 Feb 14.

34.

Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.

Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TP.

Gene Ther. 2013 Jul;20(7):761-9. doi: 10.1038/gt.2012.93. Epub 2012 Dec 20.

35.

Herpes simplex virus vector mediated gene therapy of tumor necrosis factor-α blockade for bladder overactivity and nociception in rats.

Funahashi Y, Oguchi T, Goins WF, Gotoh M, Tyagi P, Goss JR, Glorioso JC, Yoshimura N.

J Urol. 2013 Jan;189(1):366-73. doi: 10.1016/j.juro.2012.08.192. Epub 2012 Nov 19.

PMID:
23174234
36.

Novel mutations in gB and gH circumvent the requirement for known gD Receptors in herpes simplex virus 1 entry and cell-to-cell spread.

Uchida H, Chan J, Shrivastava I, Reinhart B, Grandi P, Glorioso JC, Cohen JB.

J Virol. 2013 Feb;87(3):1430-42. doi: 10.1128/JVI.02804-12. Epub 2012 Nov 14.

37.

Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.

Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC.

Mol Ther. 2013 Mar;21(3):561-9. doi: 10.1038/mt.2012.211. Epub 2012 Oct 16.

38.

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus.

Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P.

Adv Virol. 2012;2012:815465. doi: 10.1155/2012/815465. Epub 2012 Aug 13.

39.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

40.

Gene therapy for the treatment of chronic peripheral nervous system pain.

Goins WF, Cohen JB, Glorioso JC.

Neurobiol Dis. 2012 Nov;48(2):255-70. doi: 10.1016/j.nbd.2012.05.005. Epub 2012 Jun 2. Review.

41.

Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression.

Zhu X, McTiernan CF, Rajagopalan N, Shah H, Fischer D, Toyoda Y, Letts D, Bortinger J, Gibson G, Xiang W, McCurry K, Mathier M, Glorioso JC, London B.

Hum Gene Ther. 2012 Jul;23(7):722-32. doi: 10.1089/hum.2011.108. Epub 2012 Jul 11.

42.

Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception.

Oguchi T, Funahashi Y, Yokoyama H, Nishizawa O, Goins WF, Goss JR, Glorioso JC, Yoshimura N.

Gene Ther. 2013 Feb;20(2):194-200. doi: 10.1038/gt.2012.24. Epub 2012 Mar 8.

PMID:
22402319
43.

Sox11 modulates brain-derived neurotrophic factor expression in an exon promoter-specific manner.

Salerno KM, Jing X, Diges CM, Cornuet PK, Glorioso JC, Albers KM.

J Neurosci Res. 2012 May;90(5):1011-9. doi: 10.1002/jnr.23010. Epub 2012 Feb 13.

44.

Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, Kaur B.

Cancer Res. 2012 Mar 15;72(6):1353-62. doi: 10.1158/0008-5472.CAN-11-2526. Epub 2012 Jan 26.

45.

Non-coding RNAs and the advent of new directions in therapeutics.

Glorioso JC.

Gene Ther. 2011 Dec;18(12):1103. doi: 10.1038/gt.2011.150. No abstract available.

PMID:
22158030
46.

The transcription factor Sox11 promotes nerve regeneration through activation of the regeneration-associated gene Sprr1a.

Jing X, Wang T, Huang S, Glorioso JC, Albers KM.

Exp Neurol. 2012 Jan;233(1):221-32. doi: 10.1016/j.expneurol.2011.10.005. Epub 2011 Oct 14.

47.

Gene therapy for pain: results of a phase I clinical trial.

Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, Wolfe D.

Ann Neurol. 2011 Aug;70(2):207-12. doi: 10.1002/ana.22446. Epub 2011 Jul 27.

48.

Dedifferentiation rescues senescence of progeria cells but only while pluripotent.

Niedernhofer LJ, Glorioso JC, Robbins PD.

Stem Cell Res Ther. 2011 Jun 1;2(3):28. doi: 10.1186/scrt69.

49.

Premature aging-related peripheral neuropathy in a mouse model of progeria.

Goss JR, Stolz DB, Robinson AR, Zhang M, Arbujas N, Robbins PD, Glorioso JC, Niedernhofer LJ.

Mech Ageing Dev. 2011 Aug;132(8-9):437-42. doi: 10.1016/j.mad.2011.04.010. Epub 2011 May 11.

50.

Generation of replication-competent and -defective HSV vectors.

Goins WF, Krisky DM, Wechuck JB, Wolfe D, Huang S, Glorioso JC.

Cold Spring Harb Protoc. 2011 May 1;2011(5):pdb.prot5615. doi: 10.1101/pdb.prot5615.

PMID:
21536761

Supplemental Content

Loading ...
Support Center